Structure of grepafloxacin relative to activity and safety profile

Clinical Microbiology and Infection

Volumn 4, Issue SUPPL. 1, 1998, Pages

  Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ciprofloxacin; Fluoroquinolone resistance; Grepafloxacin; NorA; Respiratory pathogens; Topoisomerases

Indexed keywords

CIPROFLOXACIN; CYCLOPROPANE DERIVATIVE; GREPAFLOXACIN; METHYL GROUP; PIPERAZINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; CONFERENCE PAPER; DRUG HALF LIFE; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0031980049     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1998.tb00684.x     Document Type: Conference Paper

References (30)

1. Wise R, Andrews JM, Brenwald N. The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother 1993; 31(4): 497-504.
2. Domagala JM. Structure-activity and structure - side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685-706.
3. Wakebe H, Imada T, Yoneda H, et al. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrob Agents Chemother 1994; 38(10): 2340-5.
4. Marco F, Jones RN, Hoban DJ, Pignatari AC, Yamane N, Frei R. In vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study J Antimicrob Chemother 1994; 33(3): 647-54.
5. Sader HS, Jones RN, Allen SD, Gerlach EH, Murray PR, Washington JA. In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. J Chemother 1993; 5(5): 283-8.
6. Sewell DL, Barry AL, Allen SD, Fuchs PC, Jorgensen JH, Tenover F. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzas, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628). Diagn Microbiol Infect Dis 1995; 21(3): 175-9.
7. Gellert M, Mizuuchi K, O'Dea MH, Itoh T, Tomizawa J-I. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 1977; 74: 4772-6.
8. Sugino A, Peebles CL, Kreuzer KN, Cozzarelli NR. Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci USA 1977; 75: 4767-71.
9. Kato J-I, Nishimura Y, Yamada M, Suzuki H, Hirota Y. Gene organization in the region containing a new gene involved in chromosome partition in Escherichia coli. J Bacteriol 1988; 170: 3967-77.
10. Zechiedrich EL, Cozzarelli NR. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev 1995; 9: 2859-69.
11. Peng H, Marians KJ. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem 1993; 268: 24481-90.
12. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40: 1881-8.
13. Ng Y, Trucksis M, Hooper DC. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 1994; 38: 1345-55.
14. Trucksis M, Wolfson JS, Hooper DC. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol 1991; 173: 5854-60.
15. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.
16. Pan X-S, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 41: 471-4.
17. Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641-53.
18. Deplano A, Zekhini A, Allali N, Couturier M, Struelens MJ. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus. Antimicrob Agent Chemother 1997; 41: 2023-5.
19. Hooper DC, Chen J, Ng EY. Quinolone OPC17,116 differs from ciprofloxacin in resistance mechanisms and effects on NorA-mediated drug transport in Staphylococcus aureus [abstract A107]. 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada, USA, 1994.
20. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996; 60: 575-608.
21. Lewis K. Multidrug resistance pumps in bacteria: variations on a theme. TIBS 1994; 19: 119-23.
22. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agent Chemother 1992; 36: 695-703.
23. Poole K, Tetro K, Zhao QX, Neshat S, Heinrichs DE, Bianco N. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 1996; 40: 2021-8.
24. Neyfakh AA. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus aureus NorA protein. Antimicrob Agents Chemother 1992; 36: 484-5.
25. Markham PN, Neyfakh AA. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40(11): 2673-4.
26. Hori S, Shimada J. Effects of quinolones on the central nervous system. In: Hooper DC, Wolfson JS, eds. Quinolone antimicrobial agents. Washington DC: American Society for Microbiology, 1993: 513-26.
27. Shirasaki T, Harata N, Nakaye T, Akaike N. Interaction of various non-steroidal anti-inflammatories and quinolone antimicrobials on GABA response in rat dissociated hippocampal pyramidal neurons. Brain Res 1991; 562: 329-31.
28. Marutam K, Matsumoto M, Otabe Y, et al. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob Agents Chemother 1993; 37: 2217-23.
29. Wagai N, Tawara K. Important role of oxygen metabolites in quinolone antibacterial agent-induced cutaneous phototoxicity in mice. Arch Toxicol 1991; 65: 495-9.
30. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. Active efflux as mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 1973-8.